openPR Logo
Press release

Vascular Disrupting Agents Market Exclusive Report on Current Trends and Future Insights

12-12-2023 08:27 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Insightace analytic

Vascular Disrupting Agents Market Exclusive Report on Current

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Vascular Disrupting Agents Market (Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Liver Cancer, Mesothelioma, Non-Small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer , Renal Pelvis, and Ureter Cancer), Therapeutic Area (Hematological Malignancies, Solid Tumors), Molecules (Tubulin Binding Agents, Flavonoids, Ligand-Directed Agents), Therapy (Mono, Combination), Route of Administration (Oral, Intravenous), Product (Bavituximab, Icaritin, NGR-TNF, Padeliporfin, Plinabulin, VB-111, and Others))- Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

The Vascular Disrupting Agents Market Size is valued at 105.42 Million in 2022 and is predicted to reach 2298.64 Million by the year 2031 at a 41.4 % CAGR during the forecast period for 2023-2031.

Request For Free Sample Pages: https://www.insightaceanalytic.com/request-sample/1299

Vascular disruption agents (VDAs) are a novel category of drugs targeting tumours' blood supply. VDAs vary conceptually and operationally from currently utilized antiangiogenic medicines and exhibit high selectivity for established but aberrant tumour vasculature. Vascular disrupting agents are novel anticancer compounds with better efficacy and less toxicity. The vascular disrupting agents target the formed tumour vasculature and disrupt blood flow to cancerous tissue. These agents are currently being used for the treatment of different oncology conditions.

The high prevalence of various cancer types, growing geriatric population, fast adoption of anticancer therapies, rising patient awareness regarding the advantages of targeted therapies, increasing oncology expenditure, and rising demand for personalized drugs are expected to drive the vascular disrupting agents market during the forecast period. According to the WHO, cancer is among the leading causes of death worldwide. In 2020, estimated mortalities were 10 million and projected to reach 13 million by 2030. Further, many new anticancer therapies are being developed for various cancers (mainly solid tumours), thus offering new opportunities for the vascular disrupting agents market in the forthcoming years. However, the high cost of production and complex manufacturing processes of targeting therapies and unsatisfactory results of clinical trials may restrain the market adoption during the forecast years.

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1299

Region-wise, North America is expected to dominate this market during the forecast period. Additionally, the Asia Pacific region is likely to witness maximum growth in the next few years due to the increasing innovations of anticancer drugs & therapies, rising incidences of cancer, and growing demand for advanced therapy options.
Major market players operating in the vascular disrupting agents market include AGC Biologics (Denmark), Avid Bioservices (US), Bionomics (Australia), Beijing Shenogen Biomedical (China), Mateon Therapeutics (US), Myrexis (US), VBL Therapeutics (Israel), Steba Biotech (US), BeyondSpring Pharmaceuticals (US), Immune Pharmaceuticals (US), Nereus Pharmaceuticals (US), Madrigal Pharmaceuticals, Inc. (US), Celgene Corporation (US), Bionomics Ltd. (Australia), Lees Pharmaceutical Holdings. (Hong Kong), among others.

Key Developments in the Market:
• In April 2022, VBL Therapeutics stated that the FDA had given ofra-vec (ofranergene obadenovec or VB-111) in combination with paclitaxel Fast Track designation for the treatment of platinum-resistant ovarian cancer. VBL Therapeutics' experimental anticancer, gene-based drug Ofra-vec is being developed to treat a variety of solid tumours. The OVAL Phase 3 registration-enabling trial in patients with recurrent platinum-resistant ovarian cancer is the principal clinical initiative for ofra-vec.
• In December 2021, The US Food and Drug Administration (FDA) sent a comprehensive response letter (CRL) in response to BeyondSpring Pharmaceuticals' new drug application (NDA) requesting approval of plinabulin combined with granulocyte colony-stimulating factor (G-CSF) to prevent chemotherapy-induced neutropenia (CIN).
• In June 2021, VBL Therapeutics (Israel) provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111) for platinum-resistant treatment ovarian cancer.
• In March 2021, Steba Biotech, Padeliporfin ImPACT was given Orphan Drug Designation (ODD) for treating adult patients with upper tract urothelial cancer (UTUC). The FDA has also granted Padeliporfin ImPACT Fast Track designation for the treatment of adult patients with low-grade and unifocal high-grade UTUC.
• In January 2021, Bionomics Limited, a biopharmaceutical company, announced that all patients had completed their treatment phase in the MODULATE clinical trial, an experimental Phase 2 trial of BNC105 in combination with Bristol-Myers Squibb's nivolumab (OPDIVO) in patients with metastatic colorectal cancer.

Get Specific Chapter/Information From The Report: https://www.insightaceanalytic.com/customisation/1299

Market Segments
Global Vascular Disrupting Agents Market, by Indications, 2020-2030 (Valu US$ Mn)
• Chemotherapy-Induced Neutropenia
• Glioblastoma
• Liver Cancer
• Mesothelioma
• Non-Small Cell Lung Cancer
• Prostate Cancer
• Ovarian Cancer
• Renal Pelvis
• Ureter Cancer
Global Vascular Disrupting Agents Market, by Therapeutic Area, 2020-2030 (Valu US$ Mn)
• Hematological Malignancies
• Solid Tumors
Global Vascular Disrupting Agents Market, by Molecules, 2020-2030 (Value US$ Mn)
• Tubulin Binding Agents
• Flavonoids
• Ligand-Directed Agents
Global Vascular Disrupting Agents Market, by Therapy, 2020-2030 (Valu US$ Mn)
• Mono
• Combination
Global Vascular Disrupting Agents Market, by Route of Administration, 2020-2030 (Value US$ Mn)
• Oral
• Intravenous
Global Vascular Disrupting Agents Market, by Product, 2020-2030 (Value US$ Mn)
• Bavituximab
• Icaritin
• NGR-TNF
• Padeliporfin
• Plinabulin
• VB-111
• Others
Global Vascular Disrupting Agents Market, by Region, 2020-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global vascular disrupting agents market
 To receive an industry overview and future trends of the vascular disrupting agents market
 To analyze the vascular disrupting agents market drivers and challenges
 To get information on the vascular disrupting agents market size (Value US$ Mn) forecast to 2030
 Major investments, mergers & acquisitions in the vascular disrupting agents market industry

For More Information: https://www.insightaceanalytic.com/report/global-vascular-disrupting-agents-market/1299

Other Related Reports Published by InsightAce Analytic:
Global iPSCs Manufacturing Services Market
Global Viral and Non-Viral Vector Manufacturing Market
Global Neoantigen Cancer Vaccine Market
Global Immuno-Oncology Cell Therapy Market

Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
info@insightaceanalytic.com
North America:
+1 551 226 6109
Asia:
+91 79 72967118

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Vascular Disrupting Agents Market Exclusive Report on Current Trends and Future Insights here

News-ID: 3323968 • Views:

More Releases from Insightace analytic

Digital Pathology Market Report- Expansive Coverage on the Profit Sources
Digital Pathology Market Report- Expansive Coverage on the Profit Sources
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Pathology Market Size, Share & Trends Analysis Report By Product (Artificial Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma, Academia, Hospitals)- Market Outlook And Industry Analysis 2031" The global digital pathology market is estimated to reach over USD 2731.95 million by 2031, exhibiting a CAGR of 12.91%
Digital Health Market Future Trends and Scope Analysis Report
Digital Health Market Future Trends and Scope Analysis Report
Digital Health Market Size, Share & Trends Analysis Report By Technology (Tele-healthcare, mHealth, Healthcare Analytics, Digital Health Systems), By Component (Software, Hardware, Services), By Region, And Segment Forecasts, 2024-2031 "Digital Health Market" in terms of revenue was estimated to be worth $248.58 billion in 2023 and is poised to reach $1,004.03 billion by 2031, growing at a CAGR of 19.56% from 2023 to 2031, according to a new report by
Digital Diabetes Management Market Report on the Untapped Growth Opportunities in the Industry
Digital Diabetes Management Market Report on the Untapped Growth Opportunities i …
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Diabetes Management Market - (By Devices (Smart Glucose Meters, Continuous Glucose Monitoring Systems, And Smart Insulin Pens, Smart Insulin Pumps/ Closed-Loop Pumps & Smart Insulin Patches), Application (Diabetes & Blood Glucose Tracking Apps, Obesity & Diet Management Apps), Data Management Software & Platforms And Services), By Device Type (Handheld And Wearable Devices), By End-User(Self/Home Healthcare, Hospitals
Data Center Liquid Cooling Market Exclusive Trends Analysis with Forecast to 2031
Data Center Liquid Cooling Market Exclusive Trends Analysis with Forecast to 203 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Data Center Liquid Cooling Market Size, Share & Trends Analysis Report By End-User Industry (Financial Services And Insurance (BFSI), Banking, IT And Telecom, Government And Public Sector, Manufacturing, Healthcare, Retail), Data Center (Hyperscale, Colocation, Enterprise) And Solution (Indirect & Direct Cooling)- Market Outlook And Industry Analysis 2031" The Global Data Center Liquid Cooling Market is estimated

All 5 Releases


More Releases for Agents

uParcel Launches 'Agents Benefits' for their Delivery Agents
uParcel announced today the launch of Agent Benefits for new and current verified delivery agents which aims to expand the existing network of Delivery Agents Team. Through the Agents Benefits launches, uParcel hopes to increase the number of delivery agent signups to fulfil the increasing numbers of delivery jobs. uParcel believes in long-term investment in the delivery agents' job welfare and well-being. "We're not looking for a short-term partnership with
Flavor Masking Agents Market
Flavor Masking Agents Market: A thorough analysis of statistics about the current as well as emerging trends offers clarity regarding the Flavor Masking Agents Market dynamics. The report includes Porter’s Five Forces to analyze the prominence of various features such as the understanding of both the suppliers and customers, risks posed by various agents, the strength of competition, and promising emerging businesspersons to understand a valuable resource. Also, the report
Global Packaging Additives Market - By product (Antimicrobial Agents, Antifog Ag …
Market Research Reports Search Engine (MRRSE) has recently updated its massive report catalog by adding a fresh study titled “Global Packaging Additives Market - In-Depth Analysis with Booming Trends Supporting Growth and Forecast till 2028”. This business intelligence study encapsulates vital details about the market current as well as future status during the mentioned forecast period of 2028. The report also targets important facets such as market drivers, challenges, latest
Anti-Neoplastic Agents Market Report 2018: Segmentation by Type (alkylating and …
Global Anti-Neoplastic Agents Market Report 2018: Segmentation by Type (alkylating and alkylating-like agents, antimetabolites, antitumor antibiotics, plant alkaloids, hormonal agents, miscellaneous agents, Others) by End User (hospitals, clinics, research institutes, cancer rehabilitation centers, Others) Global Anti-Neoplastic Agents market research report provides company profile for Amgen Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Bayer AG, Aspen Holdings, Pfizer Inc., Bristol-Myers Squibb Company, Baxter Healthcare Corporation, Teva pharmaceutical Industries Ltd and Others.
Laxatives Market Lubricant Agents, Stimulant Agents, Hyperosmotic Agents, Saline …
Laxatives are chemical substances that are helpful in increasing stool motility and bowel movement, and are thus, used to treat and/or prevent constipation. Increasing incidences of medical disorders such as eating disorders where laxatives are overused and increasing incidences of constipation for which laxatives are primarily used for treatment may lead to increased consumption of laxatives, and hence, can result in laxatives market growth. Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1052 Exceeding
Global Textile Chemicals Market By Product – Surfactants, Desizing Agents, Ble …
Researchmoz added Most up-to-date research on "Global Textile Chemicals Market By Product – Surfactants, Desizing Agents, Bleaching Agents and Yarn Lubricants" to its huge collection of research reports. Textile chemicals are highly specialized chemicals incorporated in the long chemical and non-chemical processing of textiles. They are employed to impart specific properties such as water resistance, fire resistance, warp size, and others. They are utilized in processes such as scouring, bleaching, softening,